Concepedia

Maria Ignez Braghiroli

MI

Statistics

Publications

26

Citations

3.3K

H-Index

20

Active since

2006

Affiliations

Instituto do Câncer do Estado de São Paulo(Current)

Universidade de São Paulo

National Cancer Center Hospital East

Yonsei University

Hospital Sírio-Libanês

Maria Ignez Braghiroli is an author at Instituto do Câncer do Estado de São Paulo specializing in oncology, medicine, and chemotherapy.

ORCID

Publications per year

2006–2025

26

Publications

26

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang et al. · JAMA Oncology · 2020 · 1.1K citations · Full text

, , +17

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Yuichiro� Doki, Jaffer A. Ajani, Ken Kato et al. · UCL Discovery (University College London) · 2022 · 532 citations · Full text

, , +17

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

, , +16

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Thierry André, Elena Élez, Eric Van Cutsem et al. · New England Journal of Medicine · 2024 · 213 citations

, , +17

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Thierry André, Elena Élez, Heinz‐Josef Lenz et al. · The Lancet · 2025 · 179 citations

, , +12

1–5 of 26